IGNACIO DURAN
机构: Hospital Marques de Valdeciila
每年引用次数
引用次数
引用: 14,234
H-指数: 49
I10-指数 : 119
出版物: 364
Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors
S.Gail Eckhardt , Stephen Leong , Lia Gore , Lisa Wang
Molecular Cancer Therapeutics 6
2007
Biología molecular del cáncer de próstata resistente a la castración
Rafael A Medina-López , Miquel Tarón , Ignacio Osman García , Ignacio Durán Martínez
Archivos españoles de urología 71 ( 8) 639 -650
2018
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
David J. Pinato , Rafael Morales-Barrera , Petros Grivas , Gary H. Lyman
European Urology Oncology 4 ( 3) 464 -472
1
2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
David J. Pinato , Rafael Morales-Barrera , Petros Grivas , Petros Grivas
BJUI
2021
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Daniel Peter Petrylak , Thomas Powles , Jonathan E. Rosenberg , Christof Vulsteke
Journal of Clinical Oncology 39 393 -393
1
2021
TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.
Petros Grivas , Scott T Tagawa , Joaquim Bellmunt , Maria De Santis
Journal of Clinical Oncology 39
2021
Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).
Urbano Anido , Javier Puente , Ignacio Duran , Luis Costa
Journal of Clinical Oncology 39 336 -336
2021
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
Arlene O. Siefker-Radtke , Scott T. Tagawa , Robert A Huddart , Jesús García-Donas
Journal of Clinical Oncology 39 426 -426
2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
Ugo De Giorgi , Peter Grimison , Robert A Huddart , Jourik A Gietema
Journal of Clinical Oncology 39 ( 14) 1553 -1562
2021
Late Onset of Abiraterone Severe Hypokalemia Due to Unsuspected ACTH-Secreting NEC
Fernando Pazos Toral , Ignacio Duran , Isabel Alvarez Schettini
Journal of the Endocrine Society 5
2021
The role of microRNAs (miRNAs) as predictive biomarker in advanced renal cell carcinoma (mRCC) patients (pts) with “extreme response” to tyrosine kinase inhibitors (TKIs) treatment.
Carmen Garrigos , Sonia Molina-Pinelo , Marta Espinosa Montano , Antonio Lerma
Journal of Clinical Oncology 35 470 -470
1
2017
Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC).
Carmen Garrigos , Marta Espinosa , Ignacio Osman , Rainiero Ávila
Journal of Clinical Oncology 35 437 -437
2017
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.
Jose Luis Perez-Gracia , Yohann Loriot , Jonathan E. Rosenberg , Thomas Powles
Journal of Clinical Oncology 35 323 -323
6
2017
Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study.
Xavier Garcia del Muro , Miguel Angel Climent , Jose Luis Perez-Gracia , Begona Mellado
Journal of Clinical Oncology 34 4571 -4571
2016
Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.
Ignacio Duran , Miguel Angel Climent , Albert Font , M Isabel Sáez
Journal of Clinical Oncology 34 ( 15_suppl) 5058 -5058
2016
Predicting outcomes in renal cell cancer: The role of single nucleotide polymorphisms (SNPs).
Carmen Garrigos , Marta Espinosa , Ignacio Osman , Rainiero Ávila
Journal of Clinical Oncology 35
2017
MicroRNAs (miRNAs) as predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer (RCC).
Carmen Garrigos , Sonia Molina-Pinelo , Marta Espinosa , Antonio Lerma
Journal of Clinical Oncology 35
3
2017
Predictors of radiologic progression free survival (rPFS) during abiraterone acetate (AA) treatment in a randomized phase II study of AA maintenance in combination with docetaxel (D) after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): ABIDO-SOGUG trial.
Daniel Castellano , María José Méndez-Vidal , Javier Puente , M Isabel Sáez
Journal of Clinical Oncology 35
2017
Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: The ADOPTA study.
Sandra De la LLave , Laura Carpeño , Johanna Benedetti , Joan Carles
Journal of Clinical Oncology 35
1
2017
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Ali Raza Khaki , Ang Li , Leonidas N. Diamantopoulos , Mehmet A. Bilen
Cancer 126 ( 6) 1208 -1216
20
2020